(Q40640219)

22 September 2017

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma (English)

1 reference

22 September 2017

phase II clinical trial

0 references

(RS)-eflornithine

0 references

author

Bernd Walter Scheithauer

5

object named as

Scheithauer BW

1 reference

22 September 2017

Buckner JC

1

1 reference

22 September 2017

Burch PA

2

1 reference

22 September 2017

Cascino TL

3

1 reference

22 September 2017

O'Fallon JR

4

1 reference

22 September 2017

1 January 1998

1 reference

Journal of Neuro-Oncology

22 September 2017

1 reference

22 September 2017

36

1 reference

22 September 2017

1

1 reference

22 September 2017

65-70

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1005870329601

22 September 2017

0 references

cites work

Enhancement of the antiproliferative activity of human interferon by polyamine depletion

1 reference

12 December 2020

Ornithine decarboxylase as an enzyme target for therapy

1 reference

12 December 2020

Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy

1 reference

12 December 2020

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

1 reference

12 December 2020

Depletion of 9L rat brain tumor cell polyamine content by treatment with D,L-alpha-difluoromethylornithine inhibits proliferation and the G1 to S transition

1 reference

12 December 2020

Treatment of recurrent gliomas with eflornithine

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas.

1 reference

12 December 2020

Polyamines as targets for therapeutic intervention

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1005870329601

1 reference

Dimensions Publication ID

22 September 2017

0 references

1 reference